Literature DB >> 10195770

ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus.

G F Rimmelzwaan1, E C Claas, G van Amerongen, J C de Jong, A D Osterhaus.   

Abstract

Recently avian influenza A viruses of the H5N1 subtype were shown to infect humans in the Hong Kong area, resulting in the death of six people. Although these viruses did not efficiently spread amongst humans, these events illustrated that influenza viruses of subtypes not previously detected in humans could be at the basis of a new pandemic. In the light of this pandemic threat we evaluated and compared the efficacy of a classical non-adjuvanted subunit vaccine and a vaccine based on immune stimulating complexes (ISCOM) prepared with the membrane glycoproteins of the human influenza virus A/Hong Kong 156/97 (H5N1) to protect roosters against a lethal challenge with this virus. The ISCOM vaccine induced protective immunity against the challenge infection whereas the non-adjuvanted subunit vaccine proved to be poorly immunogenic and failed to induce protection in this model.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195770     DOI: 10.1016/s0264-410x(98)00390-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  15 in total

1.  Developing vaccines against pandemic influenza.

Authors:  J M Wood
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2001-12-29       Impact factor: 6.237

2.  Construction and characterization of an experimental ISCOMS-based hepatitis B polypeptide vaccine.

Authors:  Xiao-Ju Guan; Xiao-Jun Guan; Yu-Zhang Wu; Zheng-Cai Jia; Tong-Dong Shi; Yan Tang
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

Review 3.  Emerging respiratory viruses: challenges and vaccine strategies.

Authors:  Laura Gillim-Ross; Kanta Subbarao
Journal:  Clin Microbiol Rev       Date:  2006-10       Impact factor: 26.132

4.  Pathogenesis of influenza A (H5N1) virus infection in a primate model.

Authors:  G F Rimmelzwaan; T Kuiken; G van Amerongen; T M Bestebroer; R A Fouchier; A D Osterhaus
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

5.  Immunity to influenza A H9N2 viruses induced by infection and vaccination.

Authors:  X Lu; M Renshaw; T M Tumpey; G D Kelly; J Hu-Primmer; J M Katz
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

6.  Alphavirus replicon-based adjuvants enhance the immunogenicity and effectiveness of Fluzone ® in rhesus macaques.

Authors:  Timothy D Carroll; Shannon R Matzinger; Mario Barro; Linda Fritts; Michael B McChesney; Christopher J Miller; Robert E Johnston
Journal:  Vaccine       Date:  2010-11-25       Impact factor: 3.641

7.  Protection of mice against lethal infection with highly pathogenic H7N7 influenza A virus by using a recombinant low-pathogenicity vaccine strain.

Authors:  Emmie de Wit; Vincent J Munster; Monique I J Spronken; Theo M Bestebroer; Chantal Baas; Walter E P Beyer; Guus F Rimmelzwaan; Albert D M E Osterhaus; Ron A M Fouchier
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

8.  Immunization of primates with a Newcastle disease virus-vectored vaccine via the respiratory tract induces a high titer of serum neutralizing antibodies against highly pathogenic avian influenza virus.

Authors:  Joshua M DiNapoli; Lijuan Yang; Amorsolo Suguitan; Subbiah Elankumaran; David W Dorward; Brian R Murphy; Siba K Samal; Peter L Collins; Alexander Bukreyev
Journal:  J Virol       Date:  2007-08-22       Impact factor: 5.103

9.  Cationic lipid/DNA complexes (JVRS-100) combined with influenza vaccine (Fluzone) increases antibody response, cellular immunity, and antigenically drifted protection.

Authors:  Marla Lay; Bernadette Callejo; Stella Chang; David K Hong; David B Lewis; Timothy D Carroll; Shannon Matzinger; Linda Fritts; Christopher J Miller; John F Warner; Lily Liang; Jeffery Fairman
Journal:  Vaccine       Date:  2009-05-09       Impact factor: 3.641

10.  An oil-in-water nanoemulsion enhances immunogenicity of H5N1 vaccine in mice.

Authors:  Weiping Cao; William G Davis; Jin Hyang Kim; Juan A De La Cruz; Andrew Taylor; Grant R Hendrickson; Amrita Kumar; Priya Ranjan; L Andrew Lyon; Jacqueline M Katz; Shivaprakash Gangappa; Suryaprakash Sambhara
Journal:  Nanomedicine       Date:  2016-04-23       Impact factor: 5.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.